ArriVent BioPharma, Inc. AVBP Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- ArriVent BioPharma, Inc. (AVBP) reported comprehensive income (loss), net of tax, attributable to parent of -$43.6M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 32.1% year-over-year, from -$64.19M to -$43.6M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 54.8% compound annual growth rate (CAGR), from -$69.33M to -$166.08M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity resulting from both net income and other comprehensive income items during a specific period. It serves as the ultimate measure of the company's total financial performance and wealth generation for shareholders. By combining operational results with non-operational valuation changes, it offers a holistic view of the company's overall financial health.